The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
64Cu-SAR-Bombesin PET-CT imaging in the staging of ER+/PR+/HER2- metastatic breast cancer: Safety, dosimetry, and feasibility in a phase I trial.
 
Keith Wong
No Relationships to Disclose
 
Gemma Sheehan-Dare
No Relationships to Disclose
 
Andrew Nguyen
No Relationships to Disclose
 
Bao Ho
No Relationships to Disclose
 
Victor Liu
No Relationships to Disclose
 
Jonathan Lee
No Relationships to Disclose
 
Lauren Julia Brown
No Relationships to Disclose
 
Rachel Fitz-Gerald Dear
No Relationships to Disclose
 
Lyn Chan
No Relationships to Disclose
 
Sarennya Pathmanandavel
No Relationships to Disclose
 
Shikha Sharma
No Relationships to Disclose
 
Alessandra Malaroda
No Relationships to Disclose
 
Isabelle Smith
No Relationships to Disclose
 
Elgene Lim
Consulting or Advisory Role - Lilly (Inst); Novartis (Inst); Pfizer (Inst); Roche (Inst)
Research Funding - Novartis (Inst)
Patents, Royalties, Other Intellectual Property - Sensitization of BCL-2-expressing breast tumors to chemotherapy by the BH3 mimetic ABT-737
Travel, Accommodations, Expenses - Lilly
 
Louise Emmett
Honoraria - Astellas Pharma; AstraZeneca; Janssen Oncology; Mundipharma; Telix Pharmaceuticals
Consulting or Advisory Role - Noxopharm
Speakers' Bureau - Janssen Oncology; Janssen Oncology; mundipharma
Research Funding - Novartis (Inst); Novartis (Inst); Noxopharm (Inst); Noxopharm (Inst)